Annual CFI
$42.50 M
+$34.40 M+424.43%
31 December 2023
Summary:
Esperion Therapeutics annual cash flow from investing activities is currently $42.50 million, with the most recent change of +$34.40 million (+424.43%) on 31 December 2023. During the last 3 years, it has risen by +$21.14 million (+99.01%). ESPR annual CFI is now -69.74% below its all-time high of $140.45 million, reached on 31 December 2018.ESPR Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
-$167.00 K
-$90.00 K-116.88%
30 September 2024
Summary:
Esperion Therapeutics quarterly cash flow from investing activities is currently -$167.00 thousand, with the most recent change of -$90.00 thousand (-116.88%) on 30 September 2024. Over the past year, it has dropped by -$167.00 thousand (-100.00%). ESPR quarterly CFI is now -100.35% below its all-time high of $48.40 million, reached on 31 December 2017.ESPR Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$317.00 K
-$167.00 K-111.33%
30 September 2024
Summary:
Esperion Therapeutics TTM cash flow from investing activities is currently -$317.00 thousand, with the most recent change of -$167.00 thousand (-111.33%) on 30 September 2024. Over the past year, it has dropped by -$31.02 million (-101.03%). ESPR TTM CFI is now -100.20% below its all-time high of $155.86 million, reached on 31 March 2019.ESPR TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ESPR Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +424.4% | -100.0% | -101.0% |
| 3 y3 years | +99.0% | -100.0% | +97.5% |
| 5 y5 years | -69.7% | +96.9% | -100.3% |
ESPR Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +184.2% | -100.5% | +99.7% | -100.5% | +99.5% |
| 5 y | 5 years | -69.7% | +184.2% | -100.5% | +99.7% | -100.3% | +99.5% |
| alltime | all time | -69.7% | +126.5% | -100.3% | +99.9% | -100.2% | +99.8% |
Esperion Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$167.00 K(+116.9%) | -$317.00 K(+111.3%) |
| June 2024 | - | -$77.00 K(+5.5%) | -$150.00 K(-100.9%) |
| Mar 2024 | - | -$73.00 K(<-9900.0%) | $17.43 M(-59.0%) |
| Dec 2023 | $42.50 M(+424.4%) | $0.00(0.0%) | $42.50 M(+38.4%) |
| Sept 2023 | - | $0.00(-100.0%) | $30.71 M(-51.8%) |
| June 2023 | - | $17.50 M(-30.0%) | $63.71 M(+24.4%) |
| Mar 2023 | - | $25.00 M(-312.0%) | $51.21 M(+531.9%) |
| Dec 2022 | $8.10 M(-116.1%) | -$11.79 M(-135.7%) | $8.10 M(-126.5%) |
| Sept 2022 | - | $33.00 M(+560.0%) | -$30.59 M(-51.9%) |
| June 2022 | - | $5.00 M(-127.6%) | -$63.59 M(-7.3%) |
| Mar 2022 | - | -$18.10 M(-64.1%) | -$68.59 M(+35.9%) |
| Dec 2021 | -$50.48 M(-336.4%) | -$50.48 M(<-9900.0%) | -$50.48 M(+298.3%) |
| Sept 2021 | - | $0.00(0.0%) | -$12.68 M(+22.6%) |
| June 2021 | - | $0.00(0.0%) | -$10.34 M(+97.6%) |
| Mar 2021 | - | $0.00(-100.0%) | -$5.23 M(-124.5%) |
| Dec 2020 | $21.36 M(-66.8%) | -$12.68 M(-643.3%) | $21.36 M(-31.5%) |
| Sept 2020 | - | $2.33 M(-54.3%) | $31.16 M(+32.5%) |
| June 2020 | - | $5.11 M(-80.8%) | $23.52 M(-47.9%) |
| Mar 2020 | - | $26.59 M(-1027.1%) | $45.12 M(-29.7%) |
| Dec 2019 | $64.23 M(-54.3%) | -$2.87 M(-46.0%) | $64.23 M(-39.2%) |
| Sept 2019 | - | -$5.31 M(-119.9%) | $105.67 M(-30.0%) |
| June 2019 | - | $26.72 M(-41.5%) | $151.01 M(-3.1%) |
| Mar 2019 | - | $45.70 M(+18.5%) | $155.86 M(+11.0%) |
| Dec 2018 | $140.45 M(-491.7%) | $38.57 M(-3.6%) | $140.45 M(-6.5%) |
| Sept 2018 | - | $40.03 M(+26.8%) | $150.28 M(-970.1%) |
| June 2018 | - | $31.57 M(+4.2%) | -$17.27 M(-20.5%) |
| Mar 2018 | - | $30.28 M(-37.4%) | -$21.74 M(-39.4%) |
| Dec 2017 | -$35.85 M | $48.40 M(-138.0%) | -$35.85 M(-53.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2017 | - | -$127.52 M(-570.5%) | -$76.50 M(-219.4%) |
| June 2017 | - | $27.10 M(+67.6%) | $64.09 M(+13.9%) |
| Mar 2017 | - | $16.17 M(+108.6%) | $56.25 M(+455.9%) |
| Dec 2016 | $10.12 M(-106.3%) | $7.75 M(-40.7%) | $10.12 M(+31.2%) |
| Sept 2016 | - | $13.07 M(-32.1%) | $7.71 M(-118.1%) |
| June 2016 | - | $19.26 M(-164.3%) | -$42.62 M(-67.8%) |
| Mar 2016 | - | -$29.96 M(-660.6%) | -$132.48 M(-17.2%) |
| Dec 2015 | -$160.07 M(+337.4%) | $5.34 M(-114.3%) | -$160.07 M(-21.6%) |
| Sept 2015 | - | -$37.26 M(-47.2%) | -$204.30 M(+22.9%) |
| June 2015 | - | -$70.61 M(+22.7%) | -$166.25 M(+74.5%) |
| Mar 2015 | - | -$57.55 M(+48.0%) | -$95.30 M(+160.4%) |
| Dec 2014 | -$36.60 M(+74.3%) | -$38.88 M(-5053.2%) | -$36.60 M(+581.7%) |
| Sept 2014 | - | $785.00 K(+126.2%) | -$5.37 M(-72.5%) |
| June 2014 | - | $347.00 K(-69.9%) | -$19.54 M(-1.6%) |
| Mar 2014 | - | $1.15 M(-115.1%) | -$19.85 M(-5.5%) |
| Dec 2013 | -$21.00 M(>+9900.0%) | -$7.65 M(-42.8%) | -$21.00 M(+57.4%) |
| Sept 2013 | - | -$13.39 M(<-9900.0%) | -$13.35 M(<-9900.0%) |
| June 2013 | - | $37.00 K(+3600.0%) | $42.20 K(+711.5%) |
| Mar 2013 | - | $1000.00(-37.5%) | $5200.00(-360.0%) |
| Dec 2012 | -$2000.00(-100.4%) | $1600.00(-38.5%) | -$2000.00(-44.4%) |
| Sept 2012 | - | $2600.00(>+9900.0%) | -$3600.00(-41.9%) |
| June 2012 | - | $0.00(-100.0%) | -$6200.00(0.0%) |
| Mar 2012 | - | -$6200.00 | -$6200.00 |
| Dec 2011 | $509.00 K(-109.3%) | - | - |
| Dec 2002 | -$5.48 M(+157.5%) | - | - |
| Dec 2001 | -$2.13 M(+5.1%) | - | - |
| Dec 2000 | -$2.02 M(+29.5%) | - | - |
| Dec 1999 | -$1.56 M | - | - |
FAQ
- What is Esperion Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Esperion Therapeutics?
- What is Esperion Therapeutics annual CFI year-on-year change?
- What is Esperion Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Esperion Therapeutics?
- What is Esperion Therapeutics quarterly CFI year-on-year change?
- What is Esperion Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Esperion Therapeutics?
- What is Esperion Therapeutics TTM CFI year-on-year change?
What is Esperion Therapeutics annual cash flow from investing activities?
The current annual CFI of ESPR is $42.50 M
What is the all time high annual CFI for Esperion Therapeutics?
Esperion Therapeutics all-time high annual cash flow from investing activities is $140.45 M
What is Esperion Therapeutics annual CFI year-on-year change?
Over the past year, ESPR annual cash flow from investing activities has changed by +$34.40 M (+424.43%)
What is Esperion Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of ESPR is -$167.00 K
What is the all time high quarterly CFI for Esperion Therapeutics?
Esperion Therapeutics all-time high quarterly cash flow from investing activities is $48.40 M
What is Esperion Therapeutics quarterly CFI year-on-year change?
Over the past year, ESPR quarterly cash flow from investing activities has changed by -$167.00 K (-100.00%)
What is Esperion Therapeutics TTM cash flow from investing activities?
The current TTM CFI of ESPR is -$317.00 K
What is the all time high TTM CFI for Esperion Therapeutics?
Esperion Therapeutics all-time high TTM cash flow from investing activities is $155.86 M
What is Esperion Therapeutics TTM CFI year-on-year change?
Over the past year, ESPR TTM cash flow from investing activities has changed by -$31.02 M (-101.03%)